Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer
- PMID: 24452446
- PMCID: PMC4053563
- DOI: 10.1007/s13539-013-0127-5
Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer
Abstract
Background and purpose: Radiation-esophagitis and weight loss are frequently observed toxicities in patients treated with concurrent chemo-radiotherapy (CT-RT) for non-small cell lung cancer (NSCLC) and might be related. The purpose was to investigate whether weight loss already starts early after initiation of CT-RT and precedes radiation-esophagitis.
Materials and methods: In a retrospective cohort, weight and esophagitis grade ≥2 were assessed during the first weeks of (CT-)RT in patients treated with concurrent (n = 102) or sequential (n = 92) therapy. In a prospective validation study, data on body weight, esophagitis grade ≥2, nutritional intake and muscle strength were obtained before, during and following CT-RT.
Results: In the retrospective cohort, early weight loss was observed in concurrently treated patients (p = 0.002), independent of esophagitis ≥ grade 2. Early weight loss was also observed in the prospective cohort (p = 0.003) and was not accompanied by decreases in nutritional intake. In addition lower limb muscle strength rapidly declined (p = 0.042). In the later weeks of treatment, further body weight loss occurred (p < 0.001) despite increased nutritional supplementation and body weight was only partly recovered after 4 weeks post CT-RT (p = 0.003).
Conclusions: Weight loss during concurrent CT-RT for NSCLC starts early and prior to onset of esophagitis, requiring timely and intense nutritional rehabilitation.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4053563/bin/13539_2013_127_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4053563/bin/13539_2013_127_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4053563/bin/13539_2013_127_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4053563/bin/13539_2013_127_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4053563/bin/13539_2013_127_Fig5_HTML.gif)
Similar articles
-
Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469-78. doi: 10.1016/s0360-3016(98)00251-x. Int J Radiat Oncol Biol Phys. 1998. PMID: 9806503 Clinical Trial.
-
Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy.Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):689-96. doi: 10.1016/s0360-3016(00)00699-4. Int J Radiat Oncol Biol Phys. 2000. PMID: 11020565
-
Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):50-8. doi: 10.1053/srao.2002.31374. Semin Radiat Oncol. 2002. PMID: 11917285 Clinical Trial.
-
Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.Hematol Oncol Clin North Am. 2004 Feb;18(1):41-53. doi: 10.1016/s0889-8588(03)00138-2. Hematol Oncol Clin North Am. 2004. PMID: 15005280 Review.
-
Treatment-related esophagitis.Semin Oncol. 2005 Apr;32(2 Suppl 3):S60-6. doi: 10.1053/j.seminoncol.2005.03.011. Semin Oncol. 2005. PMID: 16015537 Review.
Cited by
-
Everything You Always Wanted to Know about Sarcopenia but Were Afraid to Ask: A Quick Guide for Radiation Oncologists (Impact of Sarcopenia in Radiotherapy: The AFRAID Project).Curr Oncol. 2022 Nov 8;29(11):8513-8528. doi: 10.3390/curroncol29110671. Curr Oncol. 2022. PMID: 36354731 Free PMC article. Review.
-
Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia.J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):55-67. doi: 10.1002/jcsm.12900. Epub 2022 Jan 10. J Cachexia Sarcopenia Muscle. 2022. PMID: 35014216 Free PMC article. Review.
-
Associations of Pretreatment Physical Status Parameters with Tolerance of Concurrent Chemoradiation and Survival in Patients with Non-small Cell Lung Cancer.Lung. 2021 Apr;199(2):223-234. doi: 10.1007/s00408-021-00427-9. Epub 2021 Mar 10. Lung. 2021. PMID: 33693986
-
Nutritional Interventions in Cancer Cachexia: Evidence and Perspectives From Experimental Models.Front Nutr. 2020 Dec 22;7:601329. doi: 10.3389/fnut.2020.601329. eCollection 2020. Front Nutr. 2020. PMID: 33415123 Free PMC article. Review.
-
Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.Front Nutr. 2020 Nov 26;7:600612. doi: 10.3389/fnut.2020.600612. eCollection 2020. Front Nutr. 2020. PMID: 33324671 Free PMC article.
References
-
- Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol;28:2181-2190. - PubMed
-
- Pfister DG SAL, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre J-L, Leupold N, List MA, O’Malley BO, Patel S, Marshall RP, Schwartz MA, and Wolf GT. American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. J Clin Oncol. 2006;24:3693–704. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources